Continuation of low‐molecular‐weight heparin treatment for cancer‐related venous thromboembolism: a prospective cohort study in daily clinical practice

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2017-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jth.13563PMID 28012224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuation of low‐molecular‐weight heparin treatment for cancer‐related venous thromboembolism: a prospective cohort study in daily clinical practice

  2017cited by this paper
• Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study

  2016cited by this paper
• Edoxaban for treatment of venous thromboembolism in patients with cancer

  2015cited by this paper
• Treatment of Venous Thromboembolism in Ambulatory Cancer Patients in Germany: A Prospective Non-Interventional Study

  2015cited by this paper
• Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality

  2015cited by this paper
• Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

  2015cited by this paper
• Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study

  2015cited by this paper
• Meta‐analysis of the efficacy and safety of new oral anticoagulants in patients with cancer‐associated acute venous thromboembolism

  2014cited by this paper
• Meta‐analysis of the efficacy and safety of new oral anticoagulants in patients with cancer‐associated acute venous thromboembolism: comment

  2014cited by this paper
• Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants.

  2014cited by this paper
• Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis

  2014cited by this paper
• Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.

  2014cited by this paper
• Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.

  2013cited by this paper
• Diagnostic management of acute deep vein thrombosis and pulmonary embolism

  2013cited by this paper
• Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting

  2012cited by this paper
• Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

  2007cited by this paper
• Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

  2006cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

  2005cited by this paper
• Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

  2003cited by this paper
• Venous Thromboembolism and Cancer: Risks and Outcomes

  2003cited by this paper
• Effect of syringe size on bruising following subcutaneous heparin injection.

  1996cited by this paper

• Patient adherence and satisfaction with self-administration of prophylactic Low Molecular Weight Heparin (LMWH) after orthopaedic trauma surgery: a prospective observational cohort study.

  2026cites this paper
• Pulmonary Embolism in Acute Ischaemic Stroke: Evolving Evidence, Diagnostic Challenges, and a Novel Thromboinflammatory Axis Hypothesis

  2025cites this paper
• Thrombembolien in der Onkologie: Hohes Risiko, beachtliche Mortalität, moderne Therapiestrategien

  2025cites this paper
• Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation

  2025cites this paper
• Malignancy-Associated Pulmonary Embolism: Mortality, Recurrence, and Bleeding Risks

  2025cites this paper
• Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis

  2024cites this paper
• Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)

  2024cites this paper
• Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis

  2024influential citation
• Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.

  2024cites this paper
• Trousseau syndrome: management of refractory VTE.

  2024cites this paper
• Treatment of Cancer-Associated Thrombosis: An Update

  2024cites this paper
• Assessment of enoxaparin‐related knowledge, administration technique, and self‐reported adherence among women after caesarean section delivery

  2024cites this paper
• Clinical features, outcomes, and anticoagulant strategies in lung cancer-associated isolated distal deep vein thrombosis.

  2024cites this paper
• The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.

  2024cites this paper
• A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

  2023cites this paper
• Thrombembolie-Risikofaktoren und Prophylaxe Venous thromboembolism: risk factors and prophylaxis

  2023cites this paper
• Care pathways for patients with cancer-associated thrombosis: From diagnosis to long-term follow-up.

  2023cites this paper
• Risk and timing of venous thromboembolism after surgery for lung cancer: a nationwide cohort study.

  2023cites this paper
• [Venous thromboembolism: risk factors and prophylaxis].

  2023cites this paper
• Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients

  2022cites this paper
• Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective

  2022cites this paper
• A one-fits-all approach to cancer-associated thrombosis - Are we there yet?

  2022cites this paper
• Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population

  2022cites this paper
• Treatment modalities in cancer-associated venous thromboembolism (VTE).

  2022cites this paper
• Malignomassoziierte venöse Thromboembolie

  2021cites this paper
• Cancer‐Associated ThrOmboSIs – Patient‐Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes

  2021cites this paper
• Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study

  2021cites this paper
• Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis.

  2020cites this paper
• Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants

  2020cites this paper
• [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].

  2020cites this paper
• A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer

  2020cites this paper
• Polysaccharide-Based Biomaterials for Protein Delivery

  2020cites this paper
• Therapie und Prophylaxe der tumor-assoziierten venösen Thromboembolie

  2020cites this paper
• Anticoagulation therapy in cancer associated thromboembolism - new studies, new guidelines.

  2020cites this paper
• Thromboembolische Komplikationen und Thromboseprophylaxe bei fortgeschrittenen testikulären Keimzelltumoren

  2020cites this paper
• Thrombose und Antikoagulation bei Tumorpatienten

  2019cites this paper
• Risk of recurrent venous thromboembolism and bleeding in cancer patients treated with direct oral anticoagulants versus low molecular weight heparin.

  2019cites this paper
• Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism.

  2019cites this paper
• Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study

  2019cites this paper
• Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid

  2019cites this paper
• Thrombosis and Hemostasis in Cancer

  2019cites this paper
• Etiology and Management of Upper-Extremity Catheter-Related Thrombosis in Cancer Patients.

  2019cites this paper
• NOAK als alternative Therapieoption bei tumorassoziierter venöser Thromboembolie

  2019cites this paper
• Anticoagulant Activity of Sulfated Ulvan Isolated from the Green Macroalga Ulva rigida

  2019cites this paper
• Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis

  2019cites this paper
• Aalborg Universitet Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban A nationwide cohort study

  2019cites this paper
• Factors influencing patient’s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study

  2019cites this paper
• Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

  2018cites this paper
• [Two perspectives on venous thromboembolism in oncology].

  2018cites this paper
• Cancer-Associated Venous Thromboembolic Disease , Version 2 . 2018 Featured Updates to the NCCN Guidelines

  2018cites this paper
• Cancer et récidive thromboembolique veineuse : les clés d’une prise en charge optimale

  2018cites this paper
• Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism

  2018cites this paper
• Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

  2018cites this paper
• Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer

  2018cites this paper
• Management of venous thromboembolism in patients with cancer

  2018cites this paper
• Management and treatment of deep vein thrombosis in special populations

  2018cites this paper
• Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.

  2017cites this paper
• When can we stop anticoagulation in patients with cancer-associated thrombosis?

  2017cites this paper
• When can we stop anticoagulation in patients with cancer-associated thrombosis?

  2017cites this paper
• Management of incidental pulmonary embolism

  2017cites this paper
• Continuation of low‐molecular‐weight heparin treatment for cancer‐related venous thromboembolism: a prospective cohort study in daily clinical practice

  2017cites this paper
• Use of Vena Cava Filters and Venous Access Devices

  2013cites this paper